Side Effects, Monitoring, and Life with MAC
At a Glance
MAC treatment requires regular sputum cultures to track whether the bacteria are clearing, safety checks for vision, hearing, liver, kidneys, and heart, plus daily airway clearance and good nutrition to support lung health.
Managing Mycobacterium avium complex (MAC) is a marathon that typically lasts 18 months or longer [1]. Because the medications are powerful and the treatment course is long, the focus of your care will shift from just “taking pills” to a comprehensive strategy of monitoring for side effects, tracking your progress, and physically clearing your lungs [2][3].
Medication Monitoring: Protecting Your Senses
The antibiotics used to treat MAC can affect your vision, hearing, and vital organs. Staying ahead of these side effects through regular testing is a standard part of high-quality care [2][4].
- Ethambutol and Your Vision: This drug carries a risk of optic neuritis (inflammation of the optic nerve), which can cause blurred vision or difficulty seeing colors, especially red and green [5][6]. You should have a baseline vision and color-blindness test before starting, followed by regular check-ups with an ophthalmologist while on the medication [2][7]. Action Plan: Contact your care team urgently for new blurred or color-distorted vision.
- Macrolides and Your Heart/Hearing: Drugs like Azithromycin or Clarithromycin can occasionally cause hearing loss or ringing in the ears (tinnitus) [2]. They can also affect your heart’s electrical rhythm, specifically the QTc interval. Your doctor may perform an ECG (heart tracing) and hearing tests to ensure these remain within safe limits [2][4]. Action Plan: Contact your care team urgently for ringing, hearing/balance changes, or palpitations/fainting.
- Rifamycins and Your Liver: Rifampin or Rifabutin can be hard on the liver. It is also normal—though startling—for these drugs to turn your urine, sweat, and tears a red-orange color [2]. You will need regular blood tests to check your liver enzymes [2][8]. Important note on interactions: Rifamycins can substantially alter ART, hormonal-contraceptive, anticoagulant, and many other medication levels. Action Plan: Have every prescription, over-the-counter medicine, and supplement checked by a clinician or pharmacist before starting it, and report yellow eyes, dark urine, or severe rash.
- Amikacin (IV or ALIS): These “aminoglycosides” require close monitoring of your kidneys and hearing [9][10]. Inhaled ALIS (Arikayce) can also cause local respiratory effects like a hoarse voice (dysphonia), cough, or shortness of breath, as well as severe risks like bronchospasm and hypersensitivity pneumonitis [11][12]. Action Plan: Report reduced urine, new/worsening wheeze, or breathlessness with ALIS.
(Note: Baseline and follow-up testing is regimen- and risk-specific, rather than every patient needing identical testing.)
The Surveillance Schedule: Tracking the Bacteria
To know if the treatment is working, your care team follows a structured schedule of tests [13]:
- Sputum Cultures: This is the most critical part of your monitoring. You will likely provide a mucus sample at regular intervals (commonly every 1-2 months) until the lab can no longer grow MAC from your samples [11][13]. When you have three consecutive negative cultures, you have reached culture conversion [11].
- Imaging (CT Scans and X-rays): While cultures tell us if the bacteria are alive, imaging shows the physical state of your lungs [14]. Imaging is individualized; there is no single routine schedule. You may have a chest X-ray, with CT scans used selectively to check for major changes in nodules or cavities [15][16].
- Lung Function Tests: Periodic spirometry or full pulmonary function tests help ensure that the infection isn’t causing a decline in your overall lung capacity, but they are individualized and do not replace sputum cultures [17][18].
Daily Management: Clearing the Path
For many patients, airway clearance is a vital part of daily management. Since MAC often lives in the mucus trapped in damaged airways (bronchiectasis), physically moving that mucus out of your body is vital [19][20].
- Nebulized Saline: Using a nebulizer to breathe in isotonic or hypertonic saline (salt water) helps hydrate and loosen thick mucus, making it easier to cough up [20][21]. Crucial safety rule: You should use only clinician-recommended sterile saline (never tap water or homemade solution, which can introduce new infections). Ask about bronchospasm and whether you should use a bronchodilator first.
- Clearance Techniques: Your care team may teach you the Active Cycle of Breathing or huff coughing to move mucus without exhausting yourself [19].
- Oscillatory PEP Devices: These handheld devices (like a flutter valve) create vibrations in your chest as you exhale, helping to “shake” the mucus loose from the airway walls [20].
- Lifestyle & Nutrition: Maintaining a healthy body weight (BMI) is linked to better outcomes in MAC patients [22][23]. If you are losing weight, work with a nutritionist to increase your calorie and protein intake [19].
By combining these daily habits with medical monitoring, you can manage the impact of MAC on your life and move toward a successful recovery [2][19].
Common questions in this guide
What monitoring tests are used during MAC treatment?
What does culture conversion mean in MAC disease?
When should I report vision changes while taking ethambutol?
Can MAC antibiotics interact with my other medicines?
What side effects can happen with inhaled amikacin or Arikayce?
How can airway clearance help people with MAC?
How can I support my health during long MAC treatment?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Who will be responsible for coordinating my baseline and follow-up vision and hearing tests?
- 2.What is the specific schedule for my monthly sputum cultures, and how will I be notified of my 'culture conversion' date?
- 3.Which airway clearance device or technique do you recommend specifically for my type of lung damage?
- 4.How often will we check my liver and kidney function while I am on these medications?
- 5.Are there any of my current medications—including supplements—that might interact with my rifamycin or macrolide?
- 6.What should I do if I notice a sudden change in my hearing or if my voice becomes persistently hoarse while using ALIS?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (23)
- 1
Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management.
Daley CL, Winthrop KL
The Journal of infectious diseases 2020; (222(Suppl 4)):S199-S211 doi:10.1093/infdis/jiaa354.
PMID: 32814943 - 2
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.
Daley CL, Iaccarino JM, Lange C, et al.
The European respiratory journal 2020; (56(1)) doi:10.1183/13993003.00535-2020.
PMID: 32636299 - 3
Medications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease.
Sawka A, Burke A
Clinics in chest medicine 2023; (44(4)):815-828 doi:10.1016/j.ccm.2023.06.012.
PMID: 37890918 - 4
Pharmacotherapy for nontuberculous mycobacterial pulmonary disease.
Velagapudi M, Sanley MJ, Ased S, et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2022; (79(6)):437-445 doi:10.1093/ajhp/zxab422.
PMID: 34788375 - 5
Incidence of toxic optic neuropathy with low-dose ethambutol.
Yang HK, Park MJ, Lee JH, et al.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2016; (20(2)):261-4 doi:10.5588/ijtld.15.0275.
PMID: 26792482 - 6
Lower dose of ethambutol may reduce ocular toxicity without radiological deterioration for Mycobacterium avium complex pulmonary disease.
Ando T, Kage H, Matsumoto Y, et al.
Respiratory investigation 2021; (59(6)):777-782 doi:10.1016/j.resinv.2021.06.010.
PMID: 34389250 - 7
Association Between Low-Dose Ethambutol Therapy and Optic Neuropathy in Mycobacterium avium Complex Pulmonary Disease: A Retrospective Cohort Study Using Propensity Score Analysis.
Morimoto Y, Matsui H, Ikeda M, et al.
Open forum infectious diseases 2026; (13(3)):ofag127 doi:10.1093/ofid/ofag127.
PMID: 41846599 - 8
Variables associated with antibiotic treatment tolerance in patients with Mycobacterium avium complex pulmonary disease.
Marmor M, Sharifi H, Jacobs S, et al.
Respiratory research 2024; (25(1)):123 doi:10.1186/s12931-024-02752-y.
PMID: 38468274 - 9
Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada.
Aznar ML, Marras TK, Elshal AS, et al.
BMC pharmacology & toxicology 2019; (20(1)):37 doi:10.1186/s40360-019-0302-1.
PMID: 31159865 - 10
Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial.
Winthrop KL, Flume PA, Thomson R, et al.
Annals of the American Thoracic Society 2021; (18(7)):1147-1157 doi:10.1513/AnnalsATS.202008-925OC.
PMID: 33326356 - 11
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.
Griffith DE, Eagle G, Thomson R, et al.
American journal of respiratory and critical care medicine 2018; (198(12)):1559-1569 doi:10.1164/rccm.201807-1318OC.
PMID: 30216086 - 12
Challenges and Efficacy of Amikacin Liposome Inhalation in Real-World Refractory Mycobacterium avium Complex Pulmonary Disease.
Yanagihara T, Osaki Y, Ikeda T, et al.
Cureus 2025; (17(10)):e95192 doi:10.7759/cureus.95192.
PMID: 41281056 - 13
Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion.
Mingora CM, Garcia BA, Mange KC, et al.
BMC infectious diseases 2022; (22(1)):246 doi:10.1186/s12879-022-07250-4.
PMID: 35279081 - 14
Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after treatment initiation.
Urabe N, Sakamoto S, Shimanuki Y, et al.
BMC pulmonary medicine 2022; (22(1)):157 doi:10.1186/s12890-022-01947-7.
PMID: 35468795 - 15
Post-treatment Radiographic Severity and Mortality in Mycobacterium avium Complex Pulmonary Disease.
Kim JY, Lee S, Park H, et al.
Annals of the American Thoracic Society 2024; (21(2)):235-242 doi:10.1513/AnnalsATS.202305-407OC.
PMID: 37788406 - 16
Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation.
Urabe N, Sakamoto S, Tokita N, et al.
BMC pulmonary medicine 2024; (24(1)):442 doi:10.1186/s12890-024-03261-w.
PMID: 39256717 - 17
Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course.
Hwang JA, Kim S, Jo KW, Shim TS
The European respiratory journal 2017; (49(3)) doi:10.1183/13993003.00537-2016.
PMID: 28275170 - 18
Relationship between culture conversion and clinical outcomes in nontuberculous mycobacterial pulmonary disease: Narrative review.
Winthrop KL, Mingora CM, Varley CD, et al.
Respiratory medicine 2025; (241()):108052 doi:10.1016/j.rmed.2025.108052.
PMID: 40132751 - 19
Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review.
Youssefnia A, Pierre A, Hoder JM, et al.
Journal of thoracic disease 2022; (14(9)):3575-3597 doi:10.21037/jtd-22-410.
PMID: 36245600 - 20
Non-Cystic Fibrosis Bronchiectasis in Adults: A Review.
Barker AF, Karamooz E
JAMA 2025; (334(3)):253-264 doi:10.1001/jama.2025.2680.
PMID: 40293759 - 21
Safety profile of drugs used in non-cystic fibrosis bronchiectasis: a narrative review.
Upadhyay H, Aliberti S, Husband A, et al.
Therapeutic advances in drug safety 2024; (15()):20420986241279213 doi:10.1177/20420986241279213.
PMID: 39372891 - 22
Nonpharmacological Treatment for Nontuberculous Mycobacterial Pulmonary Disease.
Kim HJ
Tuberculosis and respiratory diseases 2024; (87(4)):451-457 doi:10.4046/trd.2024.0033.
PMID: 38659390 - 23
Nontuberculous Mycobacteria Lung Disease (NTM-LD): Current Recommendations on Diagnosis, Treatment, and Patient Management.
Pathak K, Hart S, Lande L
International journal of general medicine 2022; (15()):7619-7629 doi:10.2147/IJGM.S272690.
PMID: 36213301
This page about MAC monitoring and daily care is for informational purposes only and does not constitute medical advice. Your clinician should tailor testing and treatment to your medications, lung condition, and side effects.
Get notified when new evidence is published on Mycobacterium avium complex disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.